Massachusetts Financial Services CO Morpho Sys Ag Transaction History

Massachusetts Financial Services CO

14 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2021 Nov 10, 2021	SELL	$11.76 - $19.51 $2.77 Million - $4.59 Million	-235,377 Closed	0 $0
Q2 2021 Aug 13, 2021	SELL	$18.95 - $23.95 $8.27 Million - $10.4 Million	-436,229 Reduced 64.95%	235,377 $4.53 Million
Q1 2021 May 13, 2021	SELL	$21.56 - $30.66 $334,007 - $474,984	-15,492 Reduced 2.25%	671,606 $14.6 Million
Q4 2020 Feb 12, 2021	BUY	$24.81 - $30.33 $3.46 Million - $4.23 Million	139,365 Added 25.44%	687,098 $19.5 Million
Q3 2020 Nov 12, 2020	SELL	$30.28 - $35.72 $407,508 - $480,719	-13,458 Reduced 2.4%	547,733 $17.2 Million
Q2 2020 Aug 11, 2020	BUY	$24.08 - $33.35 $1.01 Million - $1.4 Million	42,114 Added 8.11%	561,191 $17.8 Million
Q1 2020 May 14, 2020	BUY	$18.86 - $37.36 $927,459 - $1.84 Million	49,176 Added 10.47%	519,077 $12.8 Million
Q4 2019 Feb 13, 2020	BUY	$26.07 - $36.32 $3,754 - $5,230	144 Added 0.03%	469,901 $16.8 Million
Q3 2019 Nov 05, 2019	SELL	$24.18 - $31.58 $42,726 - $55,801	-1,767 Reduced 0.37%	469,757 $12.9 Million
Q2 2019 Aug 14, 2019	BUY	$23.24 - $26.76 $1.1 Million - $1.27 Million	47,328 Added 11.16%	471,524 $11.4 Million
Q1 2019 May 13, 2019	SELL	$22.55 - $29.84 $6,291 - $8,325	-279 Reduced 0.07%	424,196 $9.64 Million
Q4 2018 Feb 08, 2019	BUY	$21.96 - $31.02 $877,323 - $1.24 Million	39,951 Added 10.39%	424,475 $10.7 Million
Q3 2018 Oct 25, 2018	SELL	$26.64 - $35.66 $1,518 - $2,032	-57 Reduced 0.01%	384,524 $10.3 Million
Q2 2018 Jul 30, 2018	BUY	$25.15 - $30.6 $9.67 Million - $11.8 Million	384,581 New	384,581 $11.7 Million

1.84M

79.8K

688K

Ticker MOR
Exchange OTC
Sector Healthcare
Industry Biotechnology
Shares Outstandng 136,614,000
Description
MorphoSys AG, a commercial-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic antibodies for patients suffering from cancer and autoimmune diseases in the United States. It offers Tafasitamab, an antibody for the treatment of B cell malignancies, including diffuse large B-cell lymphoma, f...

Get notified when there are updates to the investment portfolio of Massachusetts Financial Services CO , based on Form 13F filings with the SEC.

Stay updated on Massachusetts Financial Services CO with notifications on news.